Nitric oxide administration using an oxygen hood: a pilot trial

Area of Science:

• Neonatal Medicine
• Respiratory Physiology
• Pharmacology

Background:

• Previous research demonstrated inhaled nitric oxide (iNO) effectively reduces pulmonary hypertension in animal models.
• Elevated alveolar-arterial oxygen gradients (A-aDO2) in neonates indicate impaired gas exchange.
• This study aimed to assess the feasibility of administering iNO via oxygen hood in this specific neonatal population.

Purpose of the Study:

• To determine the feasibility of using an oxygen hood for inhaled nitric oxide (iNO) delivery in neonates.
• To evaluate the safety and preliminary efficacy of iNO in neonates with elevated A-aDO2.
• To establish a foundation for larger clinical trials on iNO for neonatal respiratory distress.

Main Methods:

• A masked, randomized controlled pilot trial was conducted.
• Inclusion criteria: gestation ≥34 weeks, age <7 days, post-ductal arterial line, and A-aDO2 of 400-600 mmHg.
• Infants received either iNO (20 ppm) or oxygen for 1 hour, followed by a 4-hour wean. Primary outcome: PaO2 at 1 hour.

Main Results:

• Four infants were randomized to the iNO group and four to the control (oxygen) group.
• Two of the four infants receiving iNO showed a significant increase in PaO2 (>100 torr).
• No significant changes in oxygenation were observed in the control group. No adverse effects like methemoglobinemia were noted. Environmental NO/NO2 levels remained minimal.

Conclusions:

• Inhaled nitric oxide administration via oxygen hood is feasible in neonates with elevated A-aDO2.
• The pilot study indicates a potential for improved oxygenation.
• Larger randomized controlled trials are necessary to confirm efficacy and define the optimal patient population for this intervention.